Top

Gepubliceerd in:

09-11-2017 | Brief Report

Baseline predictors of DMT reinitiation among patients with multiple sclerosis following an MI–CBT intervention

Auteurs: Joanie Thelen, Amanda Bruce, Delwyn Catley, Sharon Lynch, Kathy Goggin, Andrea Bradley-Ewing, Morgan Glusman, Abigail Norouzinia, Lauren Strober, Jared Bruce

Gepubliceerd in: Journal of Behavioral Medicine | Uitgave 2/2018

Abstract

Patients with multiple sclerosis (MS) are often nonadherent to their disease modifying therapy (DMT). While recent studies demonstrate enhanced DMT adherence following intervention grounded in motivational interviewing (MI), little is known about how to address DMT reinitiation among MS patients who have prematurely discontinued DMT against medical advice and do not intend to reinitiate. We examined baseline predictors of DMT reinitiation among patients with MS who discontinued medications against medical advice following a telephone-based MI and Cognitive Behavioral Therapy (MI–CBT) intervention. Following MI–CBT intervention, 66 patients reported whether or not they opted to reinitiate DMT. Rate of disease progression (β = 0.295) and perceived personal control (β = − 0.131) emerged as unique significant predictors of DMT reinitiation following intervention. Clinical characteristics and health-related beliefs may be used to prospectively identify patients most likely to reinitiate DMT following MI–CBT intervention, furthering the goal of preserving brain health and preventing neurologic decline in MS via appropriate DMT utilization. Further study is warranted to delineate potential mediators and moderators of DMT reinitiation outcomes.

vorige artikel Cancer-related loneliness mediates the relationships between social constraints and symptoms among cancer patients

volgende artikel Posttraumatic stress disorder due to acute cardiac events and aversive cognitions towards cardiovascular medications

Affleck, G., Tennen, H., Pfeiffer, C., & Fifield, J. (1987). Appraisals of control and predictability in adapting to a chronic disease. Journal of Personality and Social Psychology, 53, 273–279.CrossRefPubMed

Arnett, P. A. (2003). Neuropsychological presentation and treatment of demyelinating disorders. In U. K. P. Halligan & J. Marshall (Eds.), Handbook of Clinical neuropsychology (pp. 528–543). Oxford: Oxford University Press.

Arnett, P. A., Barwick, F. H., & Beeney, J. E. (2008). Depression in multiple sclerosis: Review and theoretical proposal. Journal of the International Neuropsychological Society, 14, 691–724. https://doi.org/10.1017/S1355617708081174 PubMed

Ashley, E. A. (2015). The precision medicine initiative: A new national effort. JAMA, 313, 2119–2120. https://doi.org/10.1001/jama.2015.3595 CrossRefPubMed

Benedict, R. H., Wahlig, E., Bakshi, R., Fishman, I., Munschauer, F., Zivadinov, R., et al. (2005). Predicting quality of life in multiple sclerosis: Accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. Journal of the Neurological Sciences, 231, 29–34. https://doi.org/10.1016/j.jns.2004.12.009 CrossRefPubMed

Berger, B. A., Liang, H., & Hudmon, K. S. (2005). Evaluation of software-based telephone counseling to enhance medication persistency among patients with multiple sclerosis. Journal of the American Pharmacists Association, 45, 466–472.CrossRefPubMed

Bruce, J., Bruce, A., Lynch, S., Strober, L., O’Bryan, S., Sobotka, D., et al. (2016). A pilot study to improve adherence among MS patients who discontinue treatment against medical advice. Journal of Behavioral Medicine, 39, 276–287. https://doi.org/10.1007/s10865-015-9694-6 CrossRefPubMed

Bruce, J. M., Hancock, L. M., & Lynch, S. G. (2010). Objective adherence monitoring in multiple sclerosis: Initial validation and association with self-report. Multiple Sclerosis Journal, 16, 112–120. https://doi.org/10.1177/1352458509351897 CrossRefPubMed

Burish, T. G., Carey, M. P., Wallston, K. A., Stein, M. J., Jamison, R. N., & Naramore Lyles, J. (1984). Health locus of control and chronic disease: An external orientation may be advantageous. Journal of Social and Clinical Psychology, 2, 326–332.CrossRef

Charles, C., Gafni, A., & Whelan, T. (1997). Shared decision-making in the medical encounter: What does it mean? (Or it takes at least two to tango). Social Science and Medicine, 44, 681–692.CrossRefPubMed

Confavreux, C., & Vukusic, S. (2006). Natural history of multiple sclerosis: A unifying concept. Brain, 129, 606–616. https://doi.org/10.1093/brain/awl007 CrossRefPubMed

Cunningham, A., Gottberg, K., von Koch, L., & Hillert, J. (2010). Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis. Acta Neurologica Scandinavica, 121, 154–160. https://doi.org/10.1111/j.1600-0404.2009.01285.x CrossRefPubMed

Finkelsztejn, A. (2014). Multiple sclerosis: Overview of disease-modifying agents. Perspectives in Medicinal Chemistry, 6, 65–72. https://doi.org/10.4137/PMC.S13213 CrossRefPubMedPubMedCentral

Fisk, J. D., Ritvo, P. G., Ross, L., Haase, D. A., Marrie, T. J., & Schlech, W. F. (1994). Measuring the functional impact of fatigue: Initial validation of the fatigue impact scale. Clinical Infectious Diseases, 18, S79–S83.CrossRefPubMed

Gafson, A., Craner, M. J., & Matthews, P. M. (2016). Personalised medicine for multiple sclerosis care. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458516672017 PubMed

Glanz, B. I., Musallam, A., Rintell, D. J., Chitnis, T., Weiner, H. L., & Healy, B. C. (2014). Treatment satisfaction in multiple sclerosis. International Journal of MS Care, 16, 68–75. https://doi.org/10.7224/1537-2073.2013-021 CrossRefPubMedPubMedCentral

Goodin, D. S. (2008). Disease-modifying therapy in multiple sclerosis: Update and clinical implications. Neurology, 71, S8–S13. https://doi.org/10.1212/WNL.0b013e31818f3d8b CrossRefPubMed

Grothe, M., Lotze, M., Langner, S., & Dressel, A. (2016). The role of global and regional gray matter volume decrease in multiple sclerosis. Journal of Neurology, 263, 1137–1145. https://doi.org/10.1007/s00415-016-8114-3 CrossRefPubMed

Hancock, L. M., Bruce, J. M., & Lynch, S. G. (2011). Exacerbation history is associated with medication and appointment adherence in MS. Journal of Behavioral Medicine, 34, 330–338. https://doi.org/10.1007/s10865-011-9316-x CrossRefPubMed

Hayes, S. C., Bissett, R. T., Korn, Z., Zettle, R. D., Cooper, L. D., & Grundt, A. M. (1999). The impact of acceptance versus control rationales on pain tolerance. The Psychological Record, 46, 33–47.CrossRef

Hoang, H., Laursen, B., Stenager, E. N., & Stenager, E. (2016). Psychiatric co-morbidity in multiple sclerosis: The risk of depression and anxiety before and after MS diagnosis. Multiple Sclerosis Journal, 22, 347–353. https://doi.org/10.1177/1352458515588973 CrossRefPubMed

Hutchinson, M. (2005). Treatment adherence: What is the best that can be achieved? The International Journal of MS Care, 12, 73.

Kraft, G. H., Freal, J. E., & Coryell, J. K. (1986). Disability, disease duration, and rehabilitation service needs in multiple sclerosis: Patient perspectives. Archives of Physical Medicine and Rehabilitation, 67, 164–168.CrossRefPubMed

Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 33, 1444–1452.CrossRefPubMed

Miller, W., & Rollnick, S. (2013). Motivational interviewing: Helping people change (3rd ed.). New York: The Guilford Press.

Mohr, D. C., Goodkin, D. E., Likosky, W., Gatto, N., Baumann, K. A., & Rudick, R. A. (1997). Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Archives of Neurology, 54, 531–533.CrossRefPubMed

Moss-Morris, R., Weinman, J., Petrie, K. J., Horne, R., Cameron, L. D., & Buick, D. (2002). The revised Illness Perception Questionnaire (IPQ-R). Psychology & Health, 17, 1–16. https://doi.org/10.1080/08870440290001494 CrossRef

Nagy, V. T., & Wolfe, G. R. (1983). Chronic illness and health locus of control beliefs. Journal of Social and Clinical Psychology, 1, 58–65.CrossRef

National Multiple Sclerosis Society. MS Prevalence. Retrieved from http://www.nationalmssociety.org/About-the-Society/MS-Prevalence

Noyes, K., & Weinstock-Guttman, B. (2013). Impact of diagnosis and early treatment on the course of multiple sclerosis. The American Journal of Managed Care, 19, s321–s331.PubMed

Reynolds, M. W., Stephen, R., Seaman, C., & Rajagopalan, K. (2010). Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Current Medical Research and Opinion, 26, 663–674. https://doi.org/10.1185/03007990903554257 CrossRefPubMed

Ritvo, P. G., Fischer, J. S., Miller, D. M., Andrews, H., Paty, D., & LaRocca, N. G. (1997). Multiple Sclerosis Quality of Life Inventory: A user’s manual. New York, NY: National Multiple Sclerosis Society.

Roxburgh, R. H., Seaman, S. R., Masterman, T., Hensiek, A. E., Sawcer, S. J., Vukusic, S., et al. (2005). Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity. Neurology, 64, 1144–1151. https://doi.org/10.1212/01.WNL.0000156155.19270.F8 CrossRefPubMed

Stewart, A. L., Hays, R. D., & Ware, J. E. (1988). The MOS short-form general health survey. Reliability and validity in a patient population. Medical Care, 26, 724–735.CrossRefPubMed

Tarrants, M., Oleen-Burkey, M., Castelli-Haley, J., & Lage, M. J. (2011). The impact of comorbid depression on adherence to therapy for multiple sclerosis. Multiple Sclerosis International, 2011, 271321. https://doi.org/10.1155/2011/271321 CrossRefPubMedPubMedCentral

Treadaway, K., Cutter, G., Salter, A., Lynch, S., Simsarian, J., Corboy, J., et al. (2009). Factors that influence adherence with disease-modifying therapy in MS. Journal of Neurology, 256, 568–576. https://doi.org/10.1007/s00415-009-0096-y CrossRefPubMed

Veit, C. T., & Ware, J. E., Jr. (1983). The structure of psychological distress and well-being in general populations. Journal of Consulting and Clinical Psychology, 51, 730–742.CrossRefPubMed

Wallston, K. A., Strudler Wallston, B., Smith, S., & Dobbins, C. J. (1987). Perceived control and health. Current Psychological Research & Reviews, 6, 5–25.CrossRef

Wilski, M., & Tasiemski, T. (2016). Illness perception, treatment beliefs, self-esteem, and self-efficacy as correlates of self-management in multiple sclerosis. Acta Neurologica Scandinavica, 133, 338–345. https://doi.org/10.1111/ane.12465 CrossRefPubMed

Zhang, T., Tremlett, H., Leung, S., Zhu, F., Kingwell, E., Fisk, J. D., et al. (2016). Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology, 86, 1287–1295. https://doi.org/10.1212/WNL.0000000000002543 CrossRefPubMedPubMedCentral

Titel: Baseline predictors of DMT reinitiation among patients with multiple sclerosis following an MI–CBT intervention
Auteurs: Joanie Thelen
Amanda Bruce
Delwyn Catley
Sharon Lynch
Kathy Goggin
Andrea Bradley-Ewing
Morgan Glusman
Abigail Norouzinia
Lauren Strober
Jared Bruce
Publicatiedatum: 09-11-2017
Uitgeverij: Springer US
Gepubliceerd in: Journal of Behavioral Medicine / Uitgave 2/2018
Print ISSN: 0160-7715
Elektronisch ISSN: 1573-3521
DOI: https://doi.org/10.1007/s10865-017-9900-9

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 2/2018

Psychological pathways from racial discrimination to cortisol in African American males and females

Cancer-related loneliness mediates the relationships between social constraints and symptoms among cancer patients

Racial (vs. self) affirmation as a protective mechanism against the effects of racial exclusion on negative affect and substance use vulnerability among black young adults

The longitudinal, bidirectional relationships between parent reports of child secondhand smoke exposure and child smoking trajectories

Episodic future thinking reduces delay discounting and cigarette demand: an investigation of the good-subject effect

The association between previous success with weight loss through dietary change and success in a lifestyle modification program